AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

CORRECTING and REPLACING PHOTO Xiromed LLC Launches Gemmily™, First-to-Market Generic to Taytulla®

November 9, 2020 GMT
Xiromed LLC Launches Gemmily™, First-to-Market Generic to Taytulla® (Photo: Business Wire)
Xiromed LLC Launches Gemmily™, First-to-Market Generic to Taytulla® (Photo: Business Wire)

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Nov 9, 2020--

Please replace the photo with the accompanying corrected photo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109006051/en/

Xiromed LLC Launches Gemmily™, First-to-Market Generic to Taytulla® (Photo: Business Wire)

ADVERTISEMENT

The release reads:

Xiromed LLC Launches Gemmily™, First-to-Market Generic to Taytulla®

Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, today announced the FDA approval of Gemmily™ (Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules), 1 mg/20 mcg, a therapeutically equivalent generic version of Taytulla®. Xiromed is the first generic to Taytulla® approved in the United States. Commercialization activities for Gemmily™ will begin immediately.

Xiromed CEO Narasimhan Mani commented, “The launch of this first-to-market generic is an important milestone for Xiromed, demonstrating the strength of our development pipeline, and further establishing our position as a leading generic pharmaceutical company in the women’s health segment. The Xiromed team is excited to offer this first generic product, furthering our commitment to providing high quality generics to patients in the US.”

Taytulla® is an estrogen/progestin combination oral contraceptive indicated for use by women to prevent pregnancy. Annual market sales for Taytulla® for the twelve month period ending August, 2020 were $157 million, according to IQVIA™.

Xiromed LLC, located in Florham Park, NJ, is the US generic division of Insud Pharma, S.L., a global pharmaceutical group headquartered in Madrid, Spain. Xiromed is focused on developing and commercializing high quality generic pharmaceutical products for the US market. In addition to its commercial portfolio of generics available in the US, Xiromed has a robust development portfolio of generic pharmaceutical products in various stages of development, including injectable, inhalation and complex generic products. Learn more at http://www.xiromed.com/usa/.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20201109006051/en/

CONTACT: Lisa DiGrazia

Senior Director of Business Strategy and Portfolio

973-803 5555 x3008

Lisa.DiGrazia@xiromed.com

KEYWORD: NEW JERSEY UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: FDA WOMEN CONSUMER HEALTH PHARMACEUTICAL

SOURCE: Xiromed LLC

Copyright Business Wire 2020.

PUB: 11/09/2020 04:58 PM/DISC: 11/09/2020 04:58 PM

http://www.businesswire.com/news/home/20201109006051/en